Lilly Joins Psychedelic Drug Race With AtaiBeckley Buyout – Merger Arbitrage Mondays

AtaiBeckley Inc. (ATAI): $7.22

Market Cap: $2.66 B

Deal Value: $2.8 B

Eli Lilly and Company (LLY) entered into a merger agreement on July 16, 2026, to acquire AtaiBeckley in a deal valued at $2.8 billion, joining a growing race among pharmaceutical giants to develop psychedelic therapies for depression and other mental health conditions.

The deal reflects growing interest in psychedelic treatments as regulations have become more supportive under the Trump administration. It also strengthens Lilly’s strategy of using profits from its successful weight-loss drugs to expand and diversify its portfolio.

Only plus or premium subscribers can access this post. Subscribe today.